Ciraparantag (acetate)

Ciraparantag (acetate)

• CAS Number: 1644388-83-9
• UNSPSC Description: Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs[1][2][3][4].
• Target Antigen: Factor Xa
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/ciraparantag-acetate.html
• Purity: 98.0
• Solubility: 10 mM in DMSO|H2O : 125 mg/mL (ultrasonic)
• Smiles: O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N.CC(O)=O.[x]
• References & Citations: [1]Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. [Content Brief]|[2]Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. [Content Brief]|[3]Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. [Content Brief]|[4]Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158. [Content Brief]
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Phase 2